MBX

MBX Biosciences, Inc. Common Stock

51.35

USD

+2.89

+5.96%

Nov 06, 15:59 UTC -5

Closed

After-Market

51.34

-0.01

-0.02%

MBX Biosciences, Inc. Common Stock (MBX) Earnings

MBX Earnings Reports

Positive Surprise Ratio

MBX beat 6 of 8 last estimates.

75%

Next Report

Date of Next Report

Mar 10, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.95

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+93.88%

MBX Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, MBX reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.84 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.95 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.46

Actual

-$1.33

Surprise

+9.05%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Genmab A/S ADS

Report Date

Nov 05, 2026 For Q3 26

Estimate

$3.86

Actual

$5.64

Surprise

+46.11%

Certara, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.09

Surprise

-0.88%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Corvus Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.20

Actual

-$0.22

Surprise

-7.06%

Ginkgo Bioworks Holdings, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.87

Actual

-$0.64

Surprise

+27.17%

Lexicon Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.05

Actual

-$0.03

Surprise

+49.41%

Tectonic Therapeutic, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.35

Actual

-$1.08

Surprise

+20.37%

SAB Biotherapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.24

Surprise

+12.85%

FAQ

What were MBX Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, MBX Biosciences, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to MBX Biosciences, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is MBX Biosciences, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 10, 2027.

What are the forecasts for MBX Biosciences, Inc. Common Stock's next earnings report?

Based on -- analysts, MBX Biosciences, Inc. Common Stock is expected to report EPS of -$0.95 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.